CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...

That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...

Moderna (MRNA) ended the recent trading session at $51.30, demonstrating a -1.54% change from the preceding day's closing price. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the ...

Moderna's full pipeline may fuel long-term growth.

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject ...

After the Food and Drug Administration initially declined to review Moderna's mRNA flu vaccine candidate, the drugmaker said Wednesday that the FDA reversed its decision and will allow Moderna to move ...